CTXR Surpasses Key Breakout Point, Ready to Explode!

Citius Pharmaceuticals (CTXR) has just announced this morning that a 44 patient study was conducted in Brazil, Lebanon, and Japan for its Mino-Lok therapy in achieving microbiological eradication of infected central venous catheters (CVCs) and it showed 95% effectiveness as compared to 83% for the control!

This is an unbelievably HUGE accomplishment and proves that CTXR is the only company in the world perfectly positioned to potentially soon capture a $1 billion marketplace worldwide for an unmet medical need! CTXR already announced last week that it received “Fast Track” status from the FDA for Mino-Lok and is currently beginning its Phase 3 trials!

CTXR looks ready to become NIA’s next major explosive gainer in the upcoming days/weeks just like Hive Blockchain (TSXV: HIVE), which gained 812.2% to a high of $6.75 per share in six weeks following NIA’s September 18th suggestion at $0.74 per share! Yesterday morning, NIA urged its members to consider taking profits on HIVE and later in the day NIA announced CTXR as its first ever Biotechnology Stock Suggestion! While HIVE sold off by $0.73 or 15.5% to $3.98 per share, CTXR began to breakout big rising $0.53 or 14.1% to $4.29 per share on 9X higher than average volume!

CTXR yesterday surpassed its key breakout point by breaking out from a bullish pennant pattern just like Bitcoin in May 2016 when NIA suggested it at $531.56!

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from a third-party for covering CTXR of $20,000 cash. Never make investment decisions based on anything NIA says. This message is meant for informational and educational purposes only and does not provide investment advice.

Leave a Reply

Your email address will not be published.